MINNEAPOLIS, April 3, 2024 /PRNewswire/ -- Bio-Techne
Corporation (NASDAQ:TECH) today announced it will showcase its
portfolio of solutions to advance cancer research from target
discovery to cell therapy development at the upcoming annual
meeting of the American Association for Cancer Research (AACR),
taking place April 5-10, 2024, in
San Diego, California.
Bio-Techne will showcase its solutions at booth #541, featuring
our market-leading portfolio of high-grade life science reagents,
immunoassays, automated proteomic analytical instruments, and
multiomics solutions that are enabling new drug discovery research,
accelerating immune cell therapy, and supporting the development of
better diagnostic tools. We will also be debuting our Journey into
the Tumor Microenvironment video experience in our booth this year.
We welcome attendees to explore how different cell types in the
tumor microenvironment promote tumor escape through this new
interactive platform.
Several scientists from the company will be presenting posters
at the conference highlighting our in-house studies in the areas of
drug discovery research, automated spatial multiomics, and the
development of novel diagnostic tools. These include investigations
into validating atypical drug combinations, analyzing the tumor
microenvironment by integrated RNA and protein profiling with
automated spatial multiomics, developing an exosome/cfDNA
methylation blood-based screen for colorectal cancer, and
monitoring ESR1 mutations by RT-qPCR in longitudinal studies
to predict endocrine therapy resistance.
"We are excited to showcase our portfolio of innovative tools,
reagents and workflow solutions that enable the scientific
discoveries necessary to advance cancer research," said
Kim Kelderman, Bio-Techne's
President and Chief Executive Officer. "Bio-Techne's portfolio
plays a critical role in the development of next-generation cancer
therapies, including workflows supporting the emerging class of
cell and gene therapies. Our broad presence at AACR will showcase
the many roles Bio-Techne plays in catalyzing advances in science
and medicine, and ultimately enabling global populations to live
healthier and longer lives."
Bio-Techne Poster Presentations:
Validation of Atypical Drug Combinations Identified from
Combination Databases
Sunday, April
7th from 1:30 PM –
5:00 PM
Presenter: Marco Pinheiro, Ph.D.
Poster Section #39, Poster Board #11, Abstract #943
Unveiling the Spatial Dynamics of the Tumor Microenvironment:
Integrated RNA and Protein Profiling on the Same Slide through
Automated Spatial Multiomics Analysis
Monday, April 8th from 1:30 PM – 5:00
PM
Presenter: Arec Manoukian, Ph.D.
Poster Section #45, Poster Board #20, Abstract #3797
A Kit Targeting Detection of ESR1 Mutations from
Circulating Exosomal RNA and Cell-Free DNA Supports Longitudinal
Studies into Endocrine Therapy Resistance in a Broadly Accessible
RT-qPCR Format
Tuesday, April
9th from 9:00 AM –
12:30 PM
Presenter: Sarah Statt, Ph.D.
Poster Section #26, Poster Board #2, Abstract #4626
Exosome Based Multiomics Combined with cfDNA Methylation
Reveals Complementary Signatures in Blood Based Liquid Biopsy that
Carry Promise for Minimally Invasive
Colorectal Cancer Screening
Wednesday, April 10th from
9:00 AM - 12:30 PM
Presenter: Kyle Manning
Poster Section #51, Poster Board #10, Abstract #LB393
Poster Presentation, In Collaboration
Bladder Cancer Risk Stratification with the Oncuria 10 plex
Bead-based Urinalysis Assay Using Three Different Luminex®
xMAP Instrumentation Platforms
Monday, April 8th from 1:30 PM - 5:00 PM
Presenter: Sunao Tanaka, Ph.D.,
Postdoctoral Scientist, Cedars-Sinai
Poster Section #44, Poster Board #29, Abstract #3773
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With thousands of products in its portfolio,
Bio-Techne generated over $1.1
billion in net sales in fiscal 2023 and has approximately
3,100 employees worldwide. For more information on Bio-Techne and
its brands, please visit http://www.bio-techne.com or follow
the Company on social media at Facebook, LinkedIn, Twitter or
YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-2024-american-association-for-cancer-research-aacr-conference-302104522.html
SOURCE Bio-Techne Corporation